今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

《被我弄丢的你》主创见面会即将举行 檀健次张婧仪共赴浪漫之约

北京 - 由韩琰执导，郑执编剧，檀健次、张婧仪主演的爱情电影《被我弄丢的你》将于3月8日全国上映。为了答谢影迷一直以来的支持，影片主创团队将于3月8日在北京举行见面会，与影迷共赴浪漫之约。

电影《被我弄丢的你》改编自郑执原著小说《被我弄丢两次的王斤斤》。影片讲述了2010年高考考场上，白晓宇（檀健次饰）第一次遇见王斤斤（张婧仪饰），就把她给“弄丢”了。四年后，他们在毕业季的求职人潮中意外重逢，然后相恋。2018年，相识八年、相爱五年的他们站在婚姻的门前踌躇不前了。他们彼此相爱却又难逃现实的重重羁绊，白晓宇会再一次弄丢王斤斤吗？

见面会将于3月8日下午2点在北京某影城举行，届时导演韩琰、编剧郑执以及主演檀健次、张婧仪将悉数到场。他们将与影迷分享电影拍摄的幕后故事，并与大家一起重温影片中的经典片段。

想参加《被我弄丢的你》主创见面会的影迷，可以关注微博观影团，并转发相关活动微博，就有机会获得入场券。

《被我弄丢的你》是一部温暖治愈的爱情电影，讲述了一段跨越八年的爱情长跑。影片不仅有高颜值的主角，还有细腻的情感表达，相信一定会引起观众的共鸣。

除了主创见面会之外，影片还将举行多项观影活动，包括映后交流、路演等。希望广大影迷能够多多关注，积极参与。